SynthesisFrontiers in oncology2022

Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis.

Xinyi Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.